A recent study indicates that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds much more quickly than those who end traditional lifestyle programs.
Findings released in a prominent medical journal shows that while obese individuals can lose substantial amounts of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"People purchasing these treatments must be aware of the danger of fast rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.
This pace of regain suggests a reversion to original weight within about a year and a half.
Analyzing Approaches
The research, which looked at 37 of trials involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
Scientists emphasize that people who lose weight through lifestyle changes alone usually experience a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Experts believe the mode of action of the drugs explains the heightened weight return.
The injections imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal may cause the system to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement leads to appetite is unsuppressed, making overeating much more probable."
A Chronic Disease?
The NHS advise the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, considering the significant potential of weight regain, the treatment is often ongoing.
This perspective is reinforced by pharmaceutical companies, who say that the findings "underscore the chronic nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
Users who have discontinued the jabs report a sudden resurgence of appetite.
"I experienced something that goes on and you're instantly ravenous," recalled a patient.
The struggle is exacerbated if individuals have not developed sustainable lifestyle or habit changes during therapy.
Widespread Use
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Use is greater among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and long-term success likely depends on combined lifestyle changes.
